GIP receptor (GIPR) belongs to the G-protein coupled receptor family, activating adenylate cyclase and increasing levels of intracellular cyclic adenosine monophosphate (cAMP) in pancreatic b cells, thereby stimulating insulin section glucosedependently. New discoveries of GIP receptor (GIPR) biology in adipose tissue, as well as findings that co-agonists for the glucagon-like peptide-1 receptor (GLP-1R) and GIPR induce greater weight loss than that seen with GLP-1R agonists alone, has led to continued interest in manipulating GIPR activity for the treatment of obesity/type 2 diabetes mellitus (T2DM).
